Montreal, Quebec–(Newsfile Corp. – November 19, 2025) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (“Defence” or the “Company”), a leading biotechnology company pioneering next-generation antibody-drug conjugate (“ADC”), is pleased to announce a major step forward in the fight against cancer that goes beyond the ADCs current limitations.

Following successful presentations and meetings at the World ADC Conference in San Diego with ADC companies as well as with industry leaders and pioneers at CPHI in Frankfurt, Defence is moving forward with the strategy to become a supplier of its Accum ® platform technology to ADC companies struggling with dosing and toxicity as well as to improve the drug delivery precision to cancer cells more effectively for the benefit of cancer

See Full Page